

Improved patient access

The first personalized ctDNA test to identify molecular residual disease and optimize treatment decisions



Affordable Pricing and Billing Options

- Natera accepts all insurance plans (i.e. Medicare, Medicare advantage, Medicaid and private insurances)
- Majority of our patients will have zero out of pocket (OOP)
- **Please note: Medicare patients with stage II/III colorectal cancer are fully covered**
- For any remaining patient responsibility, Natera has robust financial assistance programs that can be offered to all patients to ensure the test is as affordable as possible.



Order
Submission



Test
Processed



Results
reported out



Insurance
claim filed



Explanation
of Benefits
sent to patient



Patient
Billing

Natera accepts all commercial and public insurances (Medicare, Medicaid)

We are committed to make testing as affordable as possible



Medicare Coverage

- Benefits include serial use of Signatera in patients with stage II or III colorectal cancer (CRC)¹
- Benefits also include single time point use for patients with stage II or III colorectal cancer (CRC)
- Medicare patients with stage II/III are fully covered; other indications are welcome however an ABN may be required*



Commercial insurance

- We welcome all insurance plans
- We will work with patients so that cost is not a barrier for testing
- We offer an affordable cash pay rate for those patients who do not wish to use insurance.

Billing Support Services



Compassionate Care Program

At Natera, we understand that billing processes can be confusing. If a patient is uninsured or concerned about their ability to pay for testing, they can complete an online application or contact one of our Patient Coordinators at signaterapc@natera.com



Patient Coordinators

Natera's Patient Care team will proactively reach out to patients after the test is ordered, and are available to answer questions related to Signatera.

- Individually dedicated patient coordinators
- Assist with billing process and pricing
- Financial Assistance

For more information on Signatera's published studies, please visit: natera.com/oncology

For questions or financial assistance, please contact Natera's Patient Coordinators.

Phone: +1 650.489.9050
Fax: +1 650.412.1962
Email: signaterapc@natera.com

References:

1. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451.

*Please contact our Patient Coordinators for more information on when an ABN is required: signaterapc@natera.com

201 Industrial Road, Suite 410, San Carlos, CA 94070 | Main +1 650.249.9090 | Fax +1 650.730.2272 | natera.com

The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2020 Natera, Inc. All Rights Reserved. SGN_OS_PT&HCP_Insurance_Billing_20201130_NAT-8020282

